Business
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms
New migraine data builds on prior clinical studies in depression HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or
About this update from Nexalin Technology, Inc.
[{"type":"text","content":"New migraine data builds on prior clinical studies in depression\nHOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today provided an update on the growing body of clinical data supporting the potential therapeutic benefits of its second-generation (Gen-2), 15 milliamp (mA) neurostimulation device, including the results of a study in patients with migraine headaches, which indicated a substantial and statistically significant benefit in patients. The clinical trial was funded by the Company’s joint venture partner, Wider Come Limited (“Wider”), and its related companies, and was conducted at the Vertigo Center, Department of Neurology, Second Affiliated Hospital of Zhengzhou University. The results were also presented in Chin J Neuromed, a peer-reviewed scientific journal in China, which concluded that repeated treatment with Nexalin’s neurostimulation device suggests a significant reduction in the frequency and degree of pain of migraine patients. In addition, a strong safety profile was reported. As part of the clinical study, 40 migraine patients (without migraine aura) were treated at the Vertigo Center. Patients were randomly assigned 1:1 to experimental and sham groups. Treatment was administered for four consecutive weeks with a 4 week follow-up period. Efficacy and adverse reactions were assessed before treatment, at the end of treatment, and at the end of follow-up, respectively. A statistically significant improvement was achieved across all key metrics, including Visual Analog Scale (VAS), Pittsburgh Sleep Quality Index (PSQI), Hamilton Anxiety Rating Scale (HAMA), Hamilton Depression Rating Scale (HAMD) and Migraine-Specific Quality of Life Questionnaire (MSQ) scores (see charts below). All of these measures are used as standard scales in clinical practice to assess the severity and impact of migraine and related symptoms, as well as the effectiveness of treatment. Additionally, no adverse events were observed during treatment in the two groups. Migraine trial results The migraine study follows the Company’s recent clinical study in depression, which demonstrated statistically significant improvements among patients. Numerous studies have indicated an association between migraines and major depressive disorder (MDD), and depression is estimated to af...